Endocrine Abstracts

Sodium glucose co-transporter2 (SGLT2) inhibitors reduce the incidence of cardiovascular events in patients with Type 2 Diabetes Mellitus (T2DM) based on the results of recent cardiovascular outcome studies. Herein, we investigated the effects of long-term treatment with canagliflozin on biochemical and immunohistochemical markers related to atherosclerosis and atherosclerosis development in the aorta of Apolipoprotein E knockout (Apo-E(−/−)) mice. After...